Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of any of the following hematologic malignancies: * Acute myeloid leukemia (AML) meeting any of the following criteria: * First complete remission with high-risk karyotype * Translocations t(15;17) allowed only if failed first-line induction therapy OR molecular evidence of persistent disease exists * Translocations t(8;21) and inv(16) allowed only if failed first-line induction therapy * Second or subsequent complete remission * Minimal residual disease\* * Acute lymphoblastic leukemia meeting any of the following criteria: * Failed induction therapy and has minimal residual disease\* by salvage therapy * First complete remission with high-risk karyotype (e.g., t\[4;11\] or t\[9;22\]) * Relapsed disease allowed provided a second or subsequent complete remission or minimal residual disease\* is achieved * Chronic myelogenous leukemia meeting any of the following criteria: * Persistent or relapsed disease after 1 year of imatinib mesylate therapy * Accelerated phase or blast crisis * Blast crisis allowed after reinduction chemotherapy places disease in chronic phase * Myelodysplastic syndromes meeting any of the following criteria: * Refractory to medical management * Cytogenetic abnormalities predictive of transformation into acute leukemia, including 5q-, 7q-, monosomy 7 and trisomy 8, or evidence of evolution to AML (e.g., refractory anemia with excess blasts (RAEB) or RAEB in transformation) * Non-Hodgkin's lymphoma or Hodgkin's lymphoma meeting any of the following criteria: * Beyond first complete remission or failed primary induction therapy and demonstrated sensitivity to therapy during the 6 months before transplantation * Recurrent disease after autologous stem cell transplantation * Must be at least 3 months posttransplantation * Cyclin D1+ mantle cell lymphoma allowed after induction therapy and in first remission * Multiple myeloma meeting either of the following criteria: * Refractory or relapsed disease * Residual disease after autologous transplantation * Chronic lymphocytic leukemia (CLL) meeting all of the following criteria: * Peripheral blood absolute lymphocyte count greater than 5,000/mm\^3 * Small to moderate size lymphocytes and less than 55% pro-lymphocytes, atypical lymphocytes, or lymphoblasts morphologically * B-cell or T-cell * Myeloproliferative disorders, including myelofibrosis * Philadelphia negative * Availability of a HLA-A, B, and DR identical family donor OR HLA-A, B, and DR genetically matched unrelated donor * Must meet 1 of the following criteria: * At least 55 years of age at time of transplantation * Received extensive prior therapy (i.e., more than 1 year of alkylator therapy or more than 2 different prior salvage regimens) or stem cell transplantation with myeloablative conditioning (either autologous or allogeneic) * Presenting with comorbid condition (e.g., abnormal cardiac, pulmonary, or renal function and/or prior life-threatening infection) that precludes eligibility for enrollment in allogeneic transplantation protocols with full ablation conditioning * No active CNS disease NOTE: \*Defined as having no circulating blasts, absolute neutrophil count greater than 1,000/mm3 and less than 10% blasts in bone marrow at least 3 weeks after last systemic chemotherapy PATIENT CHARACTERISTICS: Age * See Disease Characteristics * Over 18 Performance status * ECOG 0-2 Life expectancy * At least 3 months Hematopoietic * See Disease Characteristics Hepatic * Bilirubin no greater than 2.0 mg/dL * ALT/AST no greater than 4 times normal Renal * See Disease Characteristics * Creatinine less than 2.0 mg/dL OR * Creatinine clearance at least 50 mL/min Cardiovascular * See Disease Characteristics * Normal cardiac function by echocardiogram or radionuclide scan * Shortening fraction or ejection fraction at least 40% of normal Pulmonary * See Disease Characteristics * DLCO at least 60% * FEV\_1 greater than 50% of predicted * Pulse oximetry greater than 85% Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * HIV negative * No uncontrolled active infection PRIOR CONCURRENT THERAPY: Biologic therapy * See Disease Characteristics * At least 2 weeks since prior biologic response modifiers, signal transduction inhibitors, or monoclonal antibodies Chemotherapy * See Disease Characteristics * At least 4 weeks since prior systemic conventional chemotherapy Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * Not specified Other * Recovered from prior therapy * No concurrent sun block/sunscreen or any cosmetic that may act as a sunscreen (e.g., lotion with SPF) on the days of scheduled ultraviolet-B light therapy